EGFR and neoplasm: In summary, we have provided evidence that nimotuzumab and cetuximab, two specifics mAb to EGFR, may increase the radiosensitivity of human U87MG tumour, enhancing the antitumour efficacy of radiation in vivo. This work may enhance our preclinical understanding of the interaction of radiation and the inhibition of the EGFR to increase radiation-induced tumour toxicity.